COVID-19 left us with despair and confusion, but researchers worldwide have not given up on the vaccine. All of the professors, researchers, and analysts are working around the clock to track and find the vaccine against SARS-Cov-2, which caused the coronavirus pandemic.
SARS was first recognized as a virus in 2003. It was initiated in China, and without any devastating effects, it vanished. The world was calm. Then it returned with force at the end of 2019, and it couldn’t have been worse.
Researchers estimate that a fast-tracked vaccine’s development will take at least 12 to 18 months to be processed enough to be a successful candidate in the market.
The market, which is already getting loaded with million types of businesses, does not need one more vaccine product that is not satisfactorily tested. An errored vaccine is as harmful as a virus. Before being 100% sure of the vaccine’s solution, researchers will not release it into the market.
An increasing number of cases – need of vaccine is now more than ever
On the dull side, the increasing number of cases in the European and Indian side – a potential second wave – is a lesson to the world not to open up too soon.
It is resulting in immediate re-lockdown imposition in the regions mentioned above. All the businesses are being closed down, except for necessary items.
Luxury and non-perishable items are not considered the best for the economy in this troubled time, while economy-balancers like estate agents and 1AP Capital are considered sustained enough for the time being.
Approved vaccine – researchers still not sure!
As for the vaccine in these countries, only one magazine is approved till yet. It is called Sputnik V – previously known as Gam-COVID-Vac.
It is developed in Gamaleya Research Institute in Moscow, Russia. On 11th August, it was approved by the Russian Federation.
Experts continued to raise their concerns over the vaccine’s safety – given that it has not been trialed in Phase 3 clinic – and it can potentially harm the severe-conditioned patients.
Worldwide collaborations in a race against COVID-19
The race against pandemic has created unpredictable partnerships and collaborations to work for the same cause. Operation Warp Speed (OWS) collaborated with a few US federal government departments, including Health and Human Services, Agriculture, Energy, and Veteran Affairs, and the private sector.
The US National Institute of Health has also collaborated with more than 18 biopharmaceutical companies to speed up the process and development of vaccine candidates for coronavirus.
The COVID-19 Prevention Trials Network (COVPN) was also established. This institution combines clinical trial networks with funds granted by the National Institute of Allergy and Infectious Disease (NIAID),
The COVAX facility, an initiative by the World Health Organization (WHO), is being set up to text and research the vaccine candidates worldwide. The US government has selected three vaccine candidates that are being evaluated in COVAX for Phase 3 trials.
The member researchers have reported that completely-developed and safe-for-human models of vaccine can take 1 to 2 years.